Member access

4-Traders Homepage  >  Shares  >  Euronext Bruxelles  >  ABLYNX    ABLX   BE0003877942

ABLYNX (ABLX)

288
Delayed Quote. Delayed Euronext Bruxelles - 01/30 04:04:33 am
10.44 EUR   -0.10%
01/22 ABLYNX : Successfully opposes patent appeal case by domantis (gsk)
01/21 ABLYNX : Announces warrant exercise
01/07 ABLYNX : TO PRESENT AT THE 33rd ANNUAL J.P. MORGAN HEALTHCARE CONFER..
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ABLYNX (D) : RECEIVES EUR 5 MILLION IN MILESTONE PAYMENT FROM ALZHEIMER'S DISEASE COLLABORATION WITH BOEHRINGER INGELHEIM

06/27/2011 | 01:05am US/Eastern

GHENT, Belgium, 27 June 2011 - Ablynx [Euronext Brussels: ABLX] today announced that it has earned a ?5 million milestone payment following Boehringer Ingelheim's decision to initiate development  with the lead Nanobody candidate that was selected in May 2010.

 

In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies against a single disease target. The collaboration has a potential value of $265 million in upfront and milestone payments plus undisclosed royalties on product sales. Boehringer Ingelheim is solely responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.

 

"We are delighted that Boehringer Ingelheim is making further progress with the Nanobody lead candidate which has the potential to be a first-in-class therapy for Alzheimer's disease and we look forward to this product advancing into the clinic in 2012. This is the second milestone payment that we have received as part of our Alzheimer's research collaboration with Boehringer Ingelheim," said Dr. Edwin Moses, Chairman and CEO of Ablynx. He added: "This programme illustrates the wide applicability and advantages of our Nanobody platform in addressing diseases as complex as Alzheimer's."

 

 

For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com

 

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com :
mailto:marieke.vermeersch@ablynx.com%20

 

Complete version of the press release:
http://hugin.info/137912/R/1526010/461786.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE

HUG#1526010
React to this article
Latest news on ABLYNX
01/26 ABLYNX : Successfully Opposes Patent Appeal Case By Domantis
01/22 ABLYNX : Successfully opposes patent appeal case by domantis (gsk)
01/21 ABLYNX : Announces warrant exercise
01/07 ABLYNX : TO PRESENT AT THE 33rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2014 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
2014 ABLYNX : OPENS RECRUITMENT FOR FIRST-IN-INFANT PHASE IIa STUDY WITH ITS ANTI-RSV..
2014 ABLYNX : ADDITIONAL CLINICAL DATA FROM THE PHASE II STUDY WITH ABLYNX'S ANTI-vWF..
2014 ABLYNX : ADDITIONAL CLINICAL DATA FROM THE PHASE II STUDY WITH ABLYNX'S ANTI-vWF..
2014 ABLYNX : reports positive results from Phase I trial of caplacizumab
2014 ABLYNX : DEMONSTRATES BIOEQUIVALENCE BETWEEN LIQUID AND LYOPHILISED FORMULATIONS..
Advertisement
Chart
Duration : Period :
ABLYNX Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF